Anti-Tumor Necrosis Factor-α Use in Pediatric Inflammatory Bowel Disease—Reports from a Romanian Center

Anti-Tumor Necrosis Factor-α Use in Pediatric Inflammatory Bowel Disease—Reports from a Romanian Center

<b>Background/Objectives:</b> The introduction of anti-tumor necrosis factor-α (anti-TNF-α) agents, particularly infliximab (IFX) and adalimumab (ADA), has significantly expanded the therapeutic arsenal for inflammatory bowel disease (IBD). While these biologics have demonstrated substan...

Full description

Saved in:
Bibliographic Details
Main Authors: Roxana Matran, Andra-Mihaela Diaconu, Andreea Maria Iordache, Irina Dijmărescu, Alexandra Coroleucă, Daniela Păcurar, Cristina Becheanu
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Pharmaceuticals
Subjects:
inflammatory bowel disease
anti-TNF-α
antidrug antibodies
acute-infusion reactions
adverse events
Online Access:https://www.mdpi.com/1424-8247/18/1/84
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1424-8247/18/1/84

Similar Items